



Assessment of the serum level of soluble CD 155 (sCD 155) as a prognostic factor in High grade Non-Hodgkin Lymphoma patients

Thesis

*Submitted for partial fulfillment of Master's Degree in
Internal Medicine*

Presented by

Youssef Adel Mohamed Afifi

(M.B., B.CH)

Faculty of Medicine - Ain Shams University

Under supervision of

Prof. Dr. Mohamed Ossman Azzazi El Messeri

Professor of Internal Medicine and Haematology

Faculty of Medicine - Ain Shams University

Prof. Dr. Hany Mohamed Abd-Allah Hegab

Professor of Internal Medicine and Haematology

Faculty of Medicine - Ain Shams University

Dr. Amro Mohamed Sedky El-Ghammaz

Assistant Professor of Internal Medicine and Haematology

Faculty of Medicine - Ain Shams University

Dr. Heba Mohamed Saber Hafez

Lecturer of Internal Medicine and Haematology

Faculty of Medicine - Ain Shams University

Faculty of Medicine - Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لَسْبَحَانَكَ لَا يَعْلَمُ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

Thanks are given to *God*, the source of all knowledge and wisdom, to whom I relate any success in my life

To *Prof. Mohamed Azzazi*, Professor of Internal Medicine and Haematology, Faculty of Medicine, Ain Shams University. I really could not express my gratitude for all of what you have taught me. You are my mentor and I will always be in debt to you for your guidance in my life, and your great help, which has allowed this work to come to fruition.

I would like to express my appreciation to *Prof. Hany Mohamed Hegab*, Professor of Internal Medicine and Haematology, Faculty of Medicine, Ain Shams University for his generous help and support throughout this work, guiding me at every step in the right direction.

I was honoured to work with *Ass.Prof. Amro Sedky*, Assistant Professor of Internal Medicine and Haematology, Faculty of Medicine, Ain Shams University for his expertise and insightful remarks, which have greatly enriched this thesis.

Words cannot express my gratitude to *Dr. Heba Saber*, Lecturer of Internal Medicine and Haematology, Faculty of Medicine, Ain Shams University, who was there at every step of the writing process with her much appreciated guidance

Youssef Adel Mohamed Afifi

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations.....	v
Introduction.....	1
Aim of the Work.....	4
Review of Literature	
☞ Introduction to Non Hodgkin Lymphoma (NHL).....	5
- Epidemiology	9
- Pathogenesis of NHL	9
- Classification of NHL.....	25
- Staging of NHL	41
- Risk stratification	44
- Diagnosis and Staging of NHL	51
- Treatment of NHL	69
☞ Soluble CD 155.....	91
Patients and Methods.....	118
Results.....	128
Discussion.....	147
Summary	161
Conclusion and Recommendations	166
References	167
Arabic Summary	١

List of Tables

Table No.	Title	Page No.
Table (1):	Revised WHO Classification of mature B cell neoplasms, mature T cell neoplasms and Natural killer cell neoplasms 2016.....	26
Table (2):	Revised 2016 WHO Classification of high grade lymphoma.....	27
Table (3):	2016 WHO Classification of DLBCL	34
Table (4):	Ann Arbor Classification and Cotswold Modifications.....	42
Table (5):	Lugano classification of NHL.....	43
Table (6):	International Prognostic Index.....	46
Table (7):	International Prognostic Index (IPI) risk groups in relation to OS and PFS	47
Table (8):	Eastern Cooperative Oncology Group (ECOG) Performance Status.....	47
Table (9):	Immunophenotypic features of common high grade B- NHL.....	59
Table (10):	Immunophenotypic features of common high grade T- NHL.....	60
Table (11):	Common chemotherapy protocols used in high grade NHL	68
Table (12):	Studies of stem cell transplanatation in DHL	78
Table (13):	CART studies involving DHL.....	83
Table (14):	Response assesment of high grade NHL according to the Lugano classification.	88
Table (15):	Canonical human NK cell checkpoints	113
Table (16):	Emerging human NK cell checkpoints.....	114
Table (17):	Independent t-test for comparison of age and Chi-square test for comparison of sex in control group and newly diagnosed patients' group.	128

List of Tables (Cont...)

Table No.	Title	Page No.
Table (18):	Frequency of initial features of the newly diagnosed high grade NHL patients' group.	130
Table (19):	Median and range of performance status and IPI in the newly diagnosed patients' group.	132
Table (20):	Mean ($\pm$ SD) and range of serum LDH level in the newly diagnosed patients' group.	133
Table (21):	Mean value ($\pm$ SD) and range of peripheral hematological laboratory parameters in the patients' group at the time of diagnosis.	134
Table (22):	Independent t-test for comparison between control group and patients' group at the time of diagnosis regarding the mean ($\pm$ SD) serum sCD155 level.	135
Table (23):	Frequency of response in the patients' group after 3 cycles of chemotherapy.	136
Table (24):	Types of high grade NHL in the patients' group and the chemotherapy received.	137
Table (25):	The correlation between clinical and laboratory parameters and serum sCD155 level in the patients' group at the time of diagnosis.	139
Table (26):	Independent t-test for comparison between patients' group parameters and the mean serum level of sCD155 (ng/ml) at presentation.	141
Table (27):	One Way ANOVA test showing the relation of the serum sCD155 level (ng/ml) at the time of diagnosis to the staging and the response after 3 cycles of chemotherapy.	143

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Normal B-cell development and lymphomagenesis	6
Figure (2):	Difference between 2016 WHO Classification and 2008 WHO Classification regarding aggressive B-cell lymphomas	29
Figure (3):	The three-marker model (Hans's algorithm) applied for the classification of diffuse large B-cell lymphoma.....	36
Figure (4):	Diffuse large B-cell non-Hodgkin lymphoma.....	59
Figure (5):	Algorithm for the initial treatment of DLBCL	75
Figure (6):	Algorithm for the treatment of relapsed DLBCL	86
Figure (7):	Algorithm for treatment of primary refractory DLBCL	86
Figure (8):	The immune effects of the poliovirus receptor	94
Figure (9):	Expression of CD155 α and CD155 β in tumor tissues was higher than that of non-tumor tissues.....	98
Figure (10):	Age representation of the control group and the newly diagnosed patient's group	129
Figure (11):	Sex distribution of the control group and the newly diagnosed patients' group	129
Figure (12):	Stages among the patients' group at the time of diagnosis	131
Figure (13):	Pie chart for bone marrow infiltration (BMI) among the patients' group at the time of diagnosis	131

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (14):	Initial features of the patients' group with newly diagnosed NHL.....	132
Figure (15):	Mean Serum sCD155 levels (ng/ml) in control group and patients' group at the time of diagnosis	135
Figure (16):	Response in the patients' group after 3 cycles of chemotherapy	136
Figure (17):	Types of high grade NHL in the study in the patients' group	138
Figure (18):	Chemotherapy protocols received among the patients' group	138
Figure (19):	The correlation between IPI and sCD155 level (ng/ml) in the patients' group at the time of diagnosis.....	140
Figure (20):	Relation between the initial serum sCD155 level (ng/ml) and bone marrow infiltration at presentation	142
Figure (21):	The relation between the initial staging of patients with newly diagnosed high grade NHL and the serum sCD155 level (ng/ml) at presentation	145
Figure (22):	The relation between the initial serum sCD155 level (ng/ml) in the patients' group at presentation and the response attained after 3 cycles of chemotherapy	145
Figure (23):	Cut-off point of CD155 detection	146

List of Abbreviations

Abb.	Full term
5PS	<i>5 point scale</i>
ALC	<i>Absolute lymphocytic count</i>
ABC	<i>Activated B cell</i>
AML	<i>Acute myeloid leukemia</i>
A	<i>Alpha</i>
ANOVA	<i>Analysis of variance</i>
ALCL	<i>Anaplastic large cell lymphoma</i>
ALK	<i>Anaplastic lymphoma kinase</i>
AB	<i>Antibody</i>
AT	<i>Antiviral based therapy</i>
ATM	<i>Ataxia telangiectasia mutated</i>
ATR	<i>Ataxia telangiectasia related</i>
AHSCT	<i>Autologous hematopoietic stem cell transplantation</i>
AZA	<i>Azathioprine</i>
Bcl 1	<i>B cell lymphoma 1</i>
Bcl 2	<i>B cell lymphoma 2</i>
BCR	<i>B cell receptor</i>
BZP	<i>Basic zipper protein</i>
B	<i>Beta</i>
BM	<i>Bone marrow</i>
BMI	<i>Bone marrow infiltration</i>
BTk	<i>Bruton tyrosine kinase</i>
BL	<i>Burkitt lymphoma</i>
CRP	<i>C reactive protein</i>
CALGB	<i>Cancer and leukemia group B</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>CARD-11</i>	<i>Caspase recruitment domain family, member 11</i>
<i>CCR-5</i>	<i>CC chemokine receptor 5</i>
<i>COO</i>	<i>Cell of origin</i>
<i>ctDNA</i>	<i>Cell-free tumor-associated DNA</i>
<i>CNS</i>	<i>Central nervous system</i>
<i>CSF</i>	<i>Cerebrospinal fluid</i>
<i>CI</i>	<i>Chemoimmunotherapy</i>
<i>CTH</i>	<i>Chemotherapy</i>
<i>CAR</i>	<i>Chimeric antigen receptor</i>
<i>CAR</i>	<i>Chimeric antigen receptors</i>
<i>CLL/SLL</i>	<i>Chronic lymphocytic leukaemia / small lymphocytic lymphoma</i>
<i>CD</i>	<i>Cluster of differentiation</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CR</i>	<i>Complete remission</i>
<i>CT</i>	<i>Computerized tomography</i>
<i>CXCL-13</i>	<i>C-X-C Motif Chemokine Ligand 13</i>
<i>CRS</i>	<i>Cytokine release syndrome</i>
<i>CIG</i>	<i>Cytoplasmic immunoglobulin</i>
δ	<i>Delta</i>
<i>DNA</i>	<i>Deoxy-ribonucleic acid</i>
<i>DLBCL</i>	<i>Diffuse large B cell lymphoma</i>
<i>DAA</i>	<i>Direct-acting antiviral</i>
<i>DFS</i>	<i>Disease free survival</i>
<i>DNAM</i>	<i>DNAX accessory molecule-1</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>DHL</i>	<i>Double hit lymphoma</i>
<i>DSB</i>	<i>Double stranded breaks</i>
<i>DEL</i>	<i>Dual expressor lymphoma</i>
<i>EMR</i>	<i>Early molecular response</i>
<i>EATL</i>	<i>Enteropathy-associated T cell lymphoma</i>
<i>ELISA</i>	<i>Enzyme linked immunosorbent assay</i>
<i>EBV</i>	<i>Epstein Barr virus</i>
<i>ESR</i>	<i>Erythrocyte sedimentation rate</i>
<i>EMA</i>	<i>European Medicines agency</i>
<i>EFS</i>	<i>Event free survival</i>
<i>FNA</i>	<i>Fine needle aspiration</i>
<i>FISH</i>	<i>Fluorescence in-situ hybridization</i>
<i>FDG</i>	<i>Fluoro-deoxy glucose</i>
<i>FL</i>	<i>Follicular lymphoma</i>
<i>FLIPI</i>	<i>Follicular lymphoma international prognostic index</i>
<i>FDA</i>	<i>Food and drug administration</i>
<i>Γ</i>	<i>Gamma</i>
<i>GEP</i>	<i>Gene expression profiling</i>
<i>GC</i>	<i>Germinal center</i>
<i>GCB</i>	<i>Germinal centre B</i>
<i>GATA</i>	<i>Globin transcription factor</i>
<i>GLUT</i>	<i>Glucose transporter</i>
<i>GVHD</i>	<i>Graft versus host disease</i>
<i>GvL</i>	<i>Graft versus leukemia</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>PPD</i>	<i>Gross product of the LDi and perpendicular diameter</i>
<i>HNSCC</i>	<i>Head and neck squamous cell carcinoma</i>
<i>HB</i>	<i>Hemoglobin</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HCC</i>	<i>Hepatocellular carcinoma</i>
<i>HDT</i>	<i>High dose therapy</i>
<i>HGBCL</i>	<i>High grade B cell lymphoma</i>
<i>HGBL</i>	<i>High grade B cell lymphoma</i>
<i>HGLUC</i>	<i>High grade B cell lymphoma unclassified</i>
<i>HMA</i>	<i>High manuronic acid-containing alginate</i>
<i>HS</i>	<i>Highly significant</i>
<i>HDAC</i>	<i>Histone deacetylase</i>
<i>HD</i>	<i>Hodgkin disease</i>
<i>HL</i>	<i>Hodgkin lymphoma</i>
<i>HHV 8</i>	<i>Human herpes virus type 8</i>
<i>HIV</i>	<i>Human immunodeficiency virus</i>
<i>HTLV</i>	<i>Human T lymphotropic virus</i>
<i>ICP</i>	<i>Immune checkpoint</i>
<i>IG</i>	<i>Immunoglobulin</i>
<i>IgVH</i>	<i>immunoglobulin variable heavy chain</i>
<i>IHC</i>	<i>Immunohistochemistry</i>
<i>ITIM</i>	<i>Immunoreceptor tyrosine-based inhibitory motif</i>
<i>ICOS</i>	<i>Inducible T-cell co-stimulator</i>
<i>IκBα</i>	<i>Inhibitor of nuclear factor kappa B</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>IFN</i>	<i>Interferon</i>
<i>IRF</i>	<i>Interferon regulatory factor</i>
<i>iPET</i>	<i>Interim FDG PET</i>
<i>IL</i>	<i>Interleukin</i>
<i>INR</i>	<i>International normalized ratio</i>
<i>IPI</i>	<i>International prognostic index</i>
<i>IQR</i>	<i>Inter-quartile range</i>
<i>Jak</i>	<i>Janus kinase</i>
<i>KFT</i>	<i>Kidney function tests</i>
<i>LDH</i>	<i>Lactate dehydrogenase</i>
<i>LVEF</i>	<i>Left ventricular ejection fraction</i>
<i>LFT</i>	<i>Liver function tests</i>
<i>LDi</i>	<i>longest transverse diameter of a lesion</i>
<i>LPL</i>	<i>Lymphoplasmacytic lymphoma</i>
<i>MMR</i>	<i>Major molecular response</i>
<i>MCL</i>	<i>Mantle cell lymphoma</i>
<i>MZL</i>	<i>Marginal zone lymphomas</i>
<i>MICA</i>	<i>MHC class 1 chain-related protein A and B</i>
<i>MiRNA</i>	<i>Micro RNA</i>
<i>MC</i>	<i>Mixed cryoglobulinemia</i>
<i>MBL</i>	<i>Monoclonal B lymphocytosis</i>
<i>MGUS</i>	<i>Monoclonal gammopathy of undetermined significance</i>
<i>MEITL</i>	<i>Monomorphic epitheliotropic intestinal T-cell lymphoma</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>MALT</i>	<i>Mucosa associated lymphoid tissue</i>
<i>MUGA</i>	<i>Multiple gated aquisition</i>
<i>MUM-1</i>	<i>Multiple myeloma oncogene 1</i>
<i>MDS</i>	<i>Myelodysplastic syndrome</i>
<i>MYD-88</i>	<i>Myeloid differentiation primary response 88</i>
<i>NCCN</i>	<i>National cancer comprehensive network</i>
<i>NK</i>	<i>Natural killer cell</i>
<i>NECL</i>	<i>Nectins and Nectin-like molecules</i>
<i>NHL</i>	<i>Non Hodgkin lymphoma</i>
<i>NS</i>	<i>Non significant</i>
<i>NOS</i>	<i>Not otherwise specified</i>
<i>NF-κB</i>	<i>Nuclear factor kappa-light-chain-enhancer of activated B cells</i>
<i>NPM</i>	<i>Nucleophosmin</i>
<i>ORR</i>	<i>Objective response rate</i>
<i>OR</i>	<i>Odds' ratio</i>
<i>OS</i>	<i>Overall survival</i>
<i>PR</i>	<i>Partial remission</i>
<i>PTT</i>	<i>Partial thromboplastin time</i>
<i>PT</i>	<i>Patient time</i>
<i>PS</i>	<i>Performance status</i>
<i>PTCL</i>	<i>peripheral T-cell lymphoma</i>
<i>PTEN</i>	<i>Phosphatase and tensin homolog</i>
<i>PI3K</i>	<i>Phosphoinositide 3-kinase</i>
<i>PVR</i>	<i>Poliovirus receptor</i>

List of Abbreviations (Cont...)

Abb.	Full term
PCR	<i>Polymerase chain reaction</i>
PET	<i>Positron emission tomography</i>
PRELUDE	<i>Prevention of Relapse in Lymphoma Using Daily Enzastaurin</i>
PEL	<i>Primary effusion lymphoma</i>
PMBL	<i>Primary mediastinal B cell lymphoma</i>
PTL	<i>Primary thyroid lymphoma</i>
PD-1	<i>Programmed cell death protein 1</i>
PFS	<i>Progression free survival</i>
PD	<i>Progressive disease</i>
PKC-β	<i>Protein kinase C beta</i>
RT	<i>Radiotherapy</i>
RIC	<i>Reduced intensity conditioning</i>
Treg	<i>Regulatory T cells</i>
R/R	<i>Relapsed / refractory</i>
RECIL	<i>Response Evaluation Criteria in Lymphomas</i>
RT-PCR	<i>Reverse transcriptase</i>
REAL	<i>Revised European America lymphoma</i>
R-IPI	<i>Revised international prognostic index</i>
RNA	<i>Ribonucleic acid</i>
SDi	<i>Shortest axis perpendicular to the LDi</i>
STAT	<i>Signal transducers and activators of transcription</i>
S	<i>Significant</i>
SAP	<i>SLAM-associated protein</i>
SYK	<i>Spleen tyrosine kinase</i>